Comparison of transforaminal and posterior lumbar interbody fusion outcomes in patients receiving a novel allograft versus rhBMP-2: a radiographic and patient-reported outcomes analysis
Journal of Neurosurgery: Spine · 2024
DOI: 10.3171/2024.2.spine23569 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Neurosurgery: Spine, 2024. Verfasst von Ummey Hani und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Carolina Neurosurgery & Spine Associates, Charlotte, North Carolina. Hauptthemen laut MEDLINE: Spinal Fusion, Bone Morphogenetic Protein 2, Recombinant Proteins, Lumbar Vertebrae. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been demonstrated to achieve the highest rates of arthrodesis in multilevel lumbar fusion but is also associated with possible perioperative morbidity. A novel allograft (OSTEOAMP) is a differentiated allograft that retains growth factors supporting bone healing. The authors sought to compare the clinical and radiographic outcomes of rhBMP-2 and the novel allograft in lumbar interbody arthrodesis to determine if the latter may be a safer and equally effective alternative to rhBMP-2 for single- and multilevel posterior or transforaminal lumbar interbody fusion (PLIF or TLIF). METHODS Patients who underwent single- or multilevel TLIF or PLIF using either OSTEOAMP or rhBMP-2 at the authors’ institution over a 2-year period were prospectively followed for 12 months. Healthcare utilization, safety measures, patient satisfaction, physical disability (measured on the Oswestry Disability Index [ODI]), back and leg pain (on the numeric rating scale [NRS]), quality of life (on the EQ-5D scale), and return to work (RTW) were prospectively recorded. For purposes of this study, this consecutive series was retrospectively analyzed and pseudarthrosis rates were assessed at 2 years of follow-up. All patients (100%) had both 12-month patient-reported outcome follow-up and 24-month clinical and radiographic follow-up. RESULTS One thousand one hundred fifty-four patients (654 treated with OSTEOAMP, 500 with rhBMP-2) were prospectively enrolled in the institutional registry. After propensity score matching, there were no significant baseline differences between 330 novel allograft and 330 rhBMP-2 cases. Perioperative morbidity and 90-day hospital readmission (3.3% vs 2.4%, p = 0.485) did not significantly differ between the novel allograft and the rhBMP-2 cases. At the 2-year follow-up, symptomatic pseudarthrosis requiring revision surgery occurred in 8 patients (2.4%) with OSTEOAMP and 6 patients (1.8%) with rhBMP-2 (p = 0.589). The overall fusion rate at 2 years was similar between groups (p = 0.213). Both groups showed significant and equivalent improvement in patient-reported outcome measures (PROMs) from baseline to 12-month follow-up, with no significant difference in 1-year mean NRS leg pain score (2.5 vs 2.7), ODI (25 vs 26), quality-adjusted life years (0.73 vs 0.73), satisfaction (83% vs 80%), or RTW (6.6 vs 7 weeks). CONCLUSIONS In the authors’ institutional experience, OSTEOAMP is a clinically viable substitute for rhBMP-2 for single- and multilevel lumbar fusion. This novel allograft provides clinically effective arthrodesis and improvements in PROMs comparable to rhBMP-2 with a similar safety profile. Additional indications and outcome assessment in longitudinal studies are needed to further characterize this allogeneic graft.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Carolina Neurosurgery & Spine Associates, Charlotte, North Carolina.
- 2SpineFirst, Atrium Health, Charlotte, North Carolina; and.
- 3Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Zitieren
APA
Hani, U., Farber, S. H., Pfortmiller, D., Kim, P. K., Bohl, M. A., Holland, C. M., & McGirt, M. J. (2024). Comparison of transforaminal and posterior lumbar interbody fusion outcomes in patients receiving a novel allograft versus rhBMP-2: a radiographic and patient-reported outcomes analysis. Journal of Neurosurgery: Spine. https://doi.org/10.3171/2024.2.spine23569
Vancouver
Hani U, Farber SH, Pfortmiller D, Kim PK, Bohl MA, Holland CM, et al. Comparison of transforaminal and posterior lumbar interbody fusion outcomes in patients receiving a novel allograft versus rhBMP-2: a radiographic and patient-reported outcomes analysis. Journal of Neurosurgery: Spine. 2024. doi:10.3171/2024.2.spine23569
BibTeX
@article{Hani2024,
author = {Hani, Ummey and Farber, S Harrison and Pfortmiller, Deborah and Kim, Paul K and Bohl, Michael A and Holland, Christopher M and McGirt, Matthew J},
title = {Comparison of transforaminal and posterior lumbar interbody fusion outcomes in patients receiving a novel allograft versus rhBMP-2: a radiographic and patient-reported outcomes analysis},
journal = {Journal of Neurosurgery: Spine},
year = {2024},
doi = {10.3171/2024.2.spine23569}
}
EUVIMED